13.00mm diameter Corneal Trephine Blades

All Day Comfort for the Upper Body...

Designed for special procedures, this Wrap-Around apron has .50mm Pb in the front and .25mm Pb in the back. The velcro fasteners are adjustable to provide the most comfortable fit....

The Buckle Apron has a 2" wide belt with a rugged side-release buck. The belt and buckle are adjustable to provide a snug and comfortable fit while still offering .50mm Pb protection....

This aron protects at 0.5 mm Pb equivalency and is 20% lighter than our Standard Back-Aid Apron - yet it contains no lead products that can be harmful to the environment!...

(Date:12/17/2009)... Helped, Healed, and Preserved Good Health , ... ... Association (IHRSA) announced today that as part of its Campaign for ... abilities to make 2010 the year we unite in a national ... daily exercise is highly valued and widely practiced. IHRSA is inviting ...

(Date:12/17/2009)... , , THURSDAY, Dec. 17 (HealthDay News) -- Among teenage ... least one of three common sexually transmitted infections -- ... becoming sexually active, a new study has found. , ... also found that it was common for these patients ... within four to six months after treatment of the ...

(Date:12/17/2009)... of Science in Human Resource Development Degree Online , ... ... -- Open enrollment has begun for Villanova’s newly online ... professionals whose busy schedules can’t accommodate a campus-based program. With ... online in March 2010, location is no longer a barrier ...

(Date:12/17/2009)... SAN DIEGO, Dec. 17 Neurocrine Biosciences, Inc. ... entered into a privately negotiated transaction to sell an ... to affiliates of Venrock at a price of $2.09 ... approximately $10 million. Neurocrine expects the financing to close ... closing conditions. ,, A shelf registration statement ...

(Date:12/17/2009)... Procedure Provides Efficient Mechanism to Pursue Approval ... Dec. 17 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: ... it has initiated the regulatory approval process ... under the Decentralized Procedure (DCP). The DCP ... company to simultaneously pursue regulatory approval for ...

... Healthy Building is the theme of this year,s conference;, learn ... in the field of electromagnetic radiation (EMR) and building science ... who are creating healthy buildings every day, NASHVILLE, Tenn., ... buildings but as a wellness professional have you ever,asked yourself, ...

... Children,s Fluoride Rinse, with Special Tinting Feature to Encourage Healthier ... ... March 11 Parents confess that kids,can be full of excuses, ... survey of parents with children ages six to 12,conducted by StrategyOne ...

... Physicians and,Nurses Against Tobacco, Inc., (PANAT) an ... petitioning Pope Benedict,XVI to condemn the production, distribution, ... of State, to declare the Vatican the first ... political, spiritual, and moral leader,to set an example ...

... in Dosimetry and Phase II Trials, with Some Patients Already Past the Expected ... Survival Time for This Population -, - Data From ... ... TUSTIN, Calif., March 11 Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ), a clinical stage ...

... - Unconscious prejudices among doctors may explain why women ... to be recommended for total knee replacement surgery, a ... Journal suggests. , Toronto researchers used two standardized ... with moderate knee osteoarthritis reporting the same symptoms of ...

... inhibitor letrozole (Femara) can reduce the risk of breast cancer ... course of tamoxifen therapy. The results of a study ... trial of letrozole will appear in the Journal of Clinical ... who chose to begin letrozole treatment after the initial trial ...

(Date:12/17/2009)... -- Instacare Corp. (OTC Bulletin Board: ISCR) a ... drugs and diagnostics and at home testing products ... and provider of e-health technologies and revolutionary cell ... as part of the preparation of its Fiscal ... two new Directors and has rejected, as unneeded, ...

(Date:12/17/2009)... Inc. (Nasdaq: ANDS ) today announced preliminary results from ... the first dose cohort, 200 mg bid, in an ongoing ... and ribavirin (SOC) in HCV patients. 56% of patients ... IU/ml) at week 4, known as R apid ... of patients receiving placebo plus SOC. ,, ANA598 ...

(Date:12/17/2009)... Resources, one of the world,s leading research and ... finds that over 70 percent of surveyed U.S. ... diabetes drugs with novel mechanisms of action versus ... need for additional DPP-IV inhibitors. Both surveyed physicians ... ability and physicians in particular say the most ...